Files
Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/122570
Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug's release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Subject (English)
Citation
Citation
FONT, Joan, et al. Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator. eLife. 2017. Vol. 6, num. e23545. ISSN 2050-084X. [consulted: 13 of June of 2026]. Available at: https://hdl.handle.net/2445/122570